2012-09-25 05:14:10 - New Pharmaceuticals market report from Datamonitor: "Advances in Delivery to the Central Nervous System"

The blood-brain barrier (BBB) and the blood cerebrospinal fluid barrier (BCSFB) exist to protect the brain, stringently regulating substances into and out of the brain. This report examines the ways in which these natural barriers may be overcome or circumvented to ensure that drugs can reach their intended target in the brain.

Scope
* Identify the five main strategies for maximizing the delivery of drugs to the brain.
* Understand the scientific basis of the most promising and recent technology advances.
* Identify the companies that are at the cutting edge of each type of delivery technology.
* Gain insight from quotes and opinions from leaders in the field of CNS drug delivery.
* Assess which types of delivery technology are

best suited to which types of drug and therapy area.


Full Report Details at
- www.fastmr.com/prod/464828_advances_in_delivery_to_the_central_n ..


Highlights

Increasingly, drug delivery specialists are harnessing endogenous BBB mechanisms such as receptormediated delivery pathways with nano-enabled platform technologies to improve the uptake and targeted delivery of substances into the brain.

Improvements in intranasal delivery devices and advances in formulation technologies have enabled researchers to deliver a wide range of substances in therapeutic doses into the olfactory regions. Medical device companies Kurve Technology, Impel NeuroPharma, and OptiNose have all developed devices that are compatible with intranasal delivery.

Chemical modification (e.g. lipidation and cationization) can be used to improve passive delivery across the blood-brain barrier but is rarely used in isolation. Permeability enhancers can be used to transiently disrupt the BBB to allow the passage of drugs into the CNS, but they have yet to be fully validated in the clinic.

Reasons to Get this Report
* Which delivery technologies can be considered for a drug that needs to achieve high CNS penetration?
* What types of chemical modification have been applied and how successful have these been?
* What role can nanotechnology play in drug delivery?
* How well validated are the delivery technologies and which have data from human trials?
* Are there in indications in which the problems of blood-brain barrier penetration can be justifiably circumvented by direct injection or implantation?

Report Table of Contents:

About the author

* Disclaimer

EXECUTIVE SUMMARY

* Strategies for drug delivery to the brain

Introduction

* Key factors in the development of improved methods of drug delivery to the central nevous system

Strategies for drug delivery to the brain

* Delivery of drugs across the BBB
* Direct injection and implantation

* Conclusions on direct injection and implantation

* Chemical modifications

* Lipidation
* Cationization
* Prodrugs
* CNS "locked" prodrugs
* Carrier-mediated prodrugs
* Receptor-mediated prodrugs
* Conclusions on chemical modifications

* Permeability enhancers

* Efflux transporter inhibitors
* Conclusions on permeability enhancers

* Nano-enabled delivery technologies

* Liposomes
* Case study: G-Technology (to-BBB Technologies BV)
* Bolaamphiphiles
* Case study: V-Smart technology (Lauren Sciences)
* Nanoparticles

* Receptor-mediated delivery technologies

* Case study: EPiC technology (Angiochem)
* Other receptor-mediated delivery technologies

* Conclusions on nano-enabled and receptor-mediated delivery technologies
* Intranasal delivery

* Mechanism of intranasal delivery
* Intranasal delivery of biopharmaceuticals
* Intranasal formulations
* Intranasal devices
* Case study: POD device (Impel NeuroPharma)
* Intranasal conclusions

* Overall conclusions

Appendix

* Scope
* Methodology

* Research methodology
* Acknowledgements

* Abbreviations
* Bibliography/references

TABLES

* Table: Products approved for intrathecal delivery
* Table: Inhibitors of blood-brain barrier efflux transporters
* Table: Receptor-mediated targeting ligands

FIGURES

* Figure: Enhancing lipophilicity may increase CNS delivery
* Figure: Schematic of the prodrug approach for CNS delivery
* Figure: Chemical structures of both exogenous and endogenous LAT substrates
* Figure: Schematic of G-Technology
* Figure: Schematic of nose-to-brain pathways for drugs
* Figure: Intranasal delivery devices

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.